悪性中皮腫治療法の世界市場2019-2023

◆英語タイトル:Global Malignant Mesothelioma Therapeutics Market 2019-2023
◆商品コード:IRTNTR31697
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年7月20日
◆ページ数:125
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、悪性中皮腫治療法の世界市場について調べ、悪性中皮腫治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、悪性中皮腫治療法の市場規模をセグメンテーション別(製品別(化学療法、その他の治療薬)、)と地域別(アジア、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は悪性中皮腫治療法の世界市場規模が2019-2023期間中に年平均7%成長すると予測しています。
・サマリー
・レポートの範囲
・悪性中皮腫治療法の市場状況
・悪性中皮腫治療法の市場規模
・悪性中皮腫治療法の市場予測
・悪性中皮腫治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(化学療法、その他の治療薬)
・悪性中皮腫治療法の顧客状況
・主要地域別市場規模:アジア、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Malignant Mesothelioma Therapeutics Market: About this market

A malignant mesothelioma is a rare form of cancer affecting the thin tissue known as mesothelium that lines the lung, chest wall, and abdomen. Technavio’s malignant mesothelioma therapeutics market analysis considers sales from both chemotherapy and other therapeutics. Our analysis also considers the sales of malignant mesothelioma therapeutics in Asia, Europe, North America, and ROW. In 2018, the chemotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing demand for chemotherapy will play a significant role in the chemotherapy segment to maintain its market position. Also, our global malignant mesothelioma therapeutics report also looks at factors such as increasing adoption of combination therapies, increasing use of asbestos for commercial purposes, and special regulatory designations. However, a long latency period of malignant mesothelioma, lack of disease-specific biomarkers in earlier stages, and development and approval of advanced devices for cancer treatment may hamper the growth of the malignant mesothelioma therapeutics industry over the forecast period.

Global Malignant Mesothelioma Therapeutics Market: Overview

Increasing the use of asbestos for commercial purposes

Exposure to asbestos is the primary risk factor for malignant mesothelioma. The significant rise in the use of asbestos in commercial purposes such as building materials, machines, and transport vehicles is causing this disease in the workers due to regular exposure. The extensive use of asbestos for commercial purpose will lead to the expansion of the global malignant mesothelioma therapeutics market at a CAGR of almost 7% during the forecast period.

Increasing awareness of malignant mesothelioma

The increasing incidence and prevalence of malignant mesothelioma across the world leading to an increasing need for awareness initiatives to diagnose and treat the disease at earlier stages. Many organizations are spreading awareness about the disease and advising workers who are regularly exposed to asbestos to undergo regular screening of malignant mesothelioma, which may prevent the disease progression to advanced stages. This increasing awareness is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global malignant mesothelioma therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global malignant mesothelioma therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading malignant mesothelioma therapeutics companies, that include Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Pfizer Inc.

Also, the malignant mesothelioma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Chemotherapy – Market size and forecast 2018-2023

Other therapeutics – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Increasing awareness of malignant mesothelioma

Development of novel therapies

Reimbursement policies for chemotherapy

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bristol-Myers Squibb Co.

Eli Lilly and Co.

F. Hoffmann-La Roche Ltd.

Merck & Co. Inc.

Pfizer Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global oncology therapeutics market

Exhibit 02: Segments of global oncology therapeutics market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Product – Market share 2018-2023 (%)

Exhibit 18: Comparison by product

Exhibit 19: Chemotherapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Chemotherapy – Year-over-year growth 2019-2023 (%)

Exhibit 21: Other therapeutics – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Other therapeutics – Year-over-year growth 2019-2023 (%)

Exhibit 23: Market opportunity by product

Exhibit 24: Customer landscape

Exhibit 25: Market share by geography 2018-2023 (%)

Exhibit 26: Geographic comparison

Exhibit 27: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 28: North America – Year-over-year growth 2019-2023 (%)

Exhibit 29: Top 3 countries in North America

Exhibit 30: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in Europe

Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Asia

Exhibit 36: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in ROW

Exhibit 39: Key leading countries

Exhibit 40: Market opportunity

Exhibit 41: Drug designations

Exhibit 42: Impact of drivers and challenges

Exhibit 43: Vendor landscape

Exhibit 44: Landscape disruption

Exhibit 45: Vendors covered

Exhibit 46: Vendor classification

Exhibit 47: Market positioning of vendors

Exhibit 48: Bristol-Myers Squibb Co. – Vendor overview

Exhibit 49: Bristol-Myers Squibb Co. – Product segments

Exhibit 50: Bristol-Myers Squibb Co. – Organizational developments

Exhibit 51: Bristol-Myers Squibb Co. – Geographic focus

Exhibit 52: Bristol-Myers Squibb Co. – Key offerings

Exhibit 53: Bristol-Myers Squibb Co. – Key customers

Exhibit 54: Eli Lilly and Co. – Vendor overview

Exhibit 55: Eli Lilly and Co. – Business segments

Exhibit 56: Eli Lilly and Co. – Organizational developments

Exhibit 57: Eli Lilly and Co. – Geographic focus

Exhibit 58: Eli Lilly and Co. – Segment focus

Exhibit 59: Eli Lilly and Co. – Key offerings

Exhibit 60: Eli Lilly and Co. – Key customers

Exhibit 61: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 62: F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 63: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 64: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 65: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 66: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 67: F. Hoffmann-La Roche Ltd. – Key customers

Exhibit 68: Merck & Co. Inc. – Vendor overview

Exhibit 69: Merck & Co. Inc. – Business segments

Exhibit 70: Merck & Co. Inc. – Organizational developments

Exhibit 71: Merck & Co. Inc. – Geographic focus

Exhibit 72: Merck & Co. Inc. – Segment focus

Exhibit 73: Merck & Co. Inc. – Key offerings

Exhibit 74: Merck & Co. Inc. – Key customers

Exhibit 75: Pfizer Inc. – Vendor overview

Exhibit 76: Pfizer Inc. – Business segments

Exhibit 77: Pfizer Inc. – Organizational developments

Exhibit 78: Pfizer Inc. – Geographic focus

Exhibit 79: Pfizer Inc. – Segment focus

Exhibit 80: Pfizer Inc. – Key offerings

Exhibit 81: Pfizer Inc. – Key customers

Exhibit 82: Validation techniques employed for market sizing

Exhibit 83: Definition of market positioning of vendors



【掲載企業】

Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Pfizer Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[悪性中皮腫治療法の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆